January 9, 2007 - The court approved the settlement, entered the orders approving the plan of allocation, the motion for attorneys’ fees and expenses, and dismissed the action with prejudice.
September 27, 2006 - The court preliminarily approved the settlement.

August 28, 2006 - Parties filed a stipulation of settlement.

October 24, 2003 - The lead plaintiffs filed an amended complaint.

March 20, 2003 - Another investor filed a complaint.

March 12, 2013 - An investor in shares of King Pharmaceuticals Inc (NYSE: KG) filed a lawsuit in the U.S. District Court for the Eastern District of Tennessee against King Pharmaceuticals Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between April 26, 1999 and March 11, 2003.

The original complaint charges King Pharmaceuticals Inc and certain of its officers with violations of Federal Securities Laws. Among other things, plaintiff claims that defendants’ material omissions and the dissemination of materially false and misleading statements concerning King Pharmaceuticals Inc’s business operations and earnings caused King Pharmaceuticals Inc’s stock price to become artificially inflated, inflicting damages on investors. King Pharmaceuticals Inc manufactures, markets and sells primarily branded prescription pharmaceutical products to general and family practitioners and internal medicine physicians and hospitals across the United States. The complaint alleges that between April 26, 1999 and March 11, 2003. defendants misrepresented that the prices paid by governmental Medicaid agencies were the “best price” - i.e., the cheapest price offered to distributors and other purchasers - for a particular drug, resulting in government overpayment for drugs purchased through the Medicaid program. The complaint further alleges that King Pharmaceuticals Inc recognized revenue subject to “pharmaceutical rebate” payments provided by King Pharmaceuticals to distributors to stock up on the Company’s blood-pressure drug, Altace(R). On March 11, 2003, defendants disclosed that the Securities and Exchange Commission is investigating King Pharmaceuticals Inc and has subpoenaed, among other things, King Pharmaceuticals Inc’s “best price” lists and all documents related to the pricing of the company’s pharmaceutical products to any governmental Medicaid agency during 1999 and the accrual and payment of rebates on Altace. News of the SEC investigation caused a 23% drop in the price of King Pharmaceuticals Inc’s (NYSE: KG) stock on the day the investigation was disclosed.